Search NLS News

SmartCella has announced a new share issue to accelerate growth and support commercialization of the Extroducer and the company’s cell and mRNA operations. The share issue was supported by existing large institutional investors such as Fjärde AP-fonden, AMF Pension and SEB-Stiftelsen, as well as a new long-term strategic investor, AstraZeneca (committing to approximately half of […]

The BIO International Convention, this year held in San Diego, California, from June 3-6, is the largest event for biotechnology and considered one of the industry’s most significant gatherings.

Orion Corporation and MSD have announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat, an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for MSD. “The conversion of this collaboration into a license agreement allows […]

Obesity is a chronic disease that requires continuous interdisciplinary research to find and develop effective new tools for prevention and treatment. NLS asked the Finnish Association for the Study of Obesity (FASO) about the Nordic region’s challenges and efforts within obesity. How would you describe the impact that drugs like semaglutide have had on obesity […]

Botond Roska and José-Alain Sahel have been awarded the Wolf Prize in Medicine for their pioneering work on restoring vision to blind patients using optogenetic therapy. The Wolf Prize recognizes outstanding achievements in various fields including medicine. Botond Roska and José-Alain Sahel Roska, Director at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and […]

Obesity is a chronic disease that requires continuous interdisciplinary research to find and develop effective new tools for prevention and treatment. NLS asked the Finnish Association for the Study of Obesity (FASO) about the Nordic region’s challenges and efforts within obesity. How would you describe the impact that drugs like semaglutide have had on obesity […]

Hadean Ventures co-led the EUR 63 million Series A financing round, together with a consortium of international investors. In conjunction with this investment, Georgina Askeland, Senior Associate at Hadean Ventures, will join SciRhom’s board of directors. “SciRhom has a unique approach that ticks all the boxes in I&I. In one stroke, their highly selective iRhom2 […]

The round is led by Danish VC Dreamcraft, together with biotech investor Lundbeckfonden BioCapital and the private investment company 2degrees. The investment will accelerate the development of Kvantify’s solutions that aim to leverage quantum computing to address complex problems in drug discovery and beyond. It will also boost the further development of quantum algorithms for […]

Sahlgrenska Science Park and Business Region Göteborg (BRG), in collaboration with Region Västra Götaland and Sahlgrenska University Hospital, have taken leading roles in the PRECISEU project. This European initiative aims to connect innovation ecosystems across Europe to efficiently advance towards truly personalized healthcare. The PRECISEU project is designed to transfer best practices and solutions across […]

Unfortunately genes do matter when it comes to obesity, but knowledge about these genes and how they work are key to improving treatment and prevention.